The Dreamy Jet Study

Launched by UNIVERSITY OF WISCONSIN, MADISON · Apr 2, 2025

Keywords

ClinConnect Summary

The Dreamy Jet Study is a clinical trial aimed at finding out if a special device, called a jet-injection system, can give children a sedative with less pain and stress compared to the usual methods. This trial is important because it focuses on making procedures like blood draws, IV placements, or immunizations easier and more comfortable for kids.

To participate in this study, children aged 2 to 15 years old who weigh less than 40 kg and are referred to the Pediatric Sedation Clinic at UW Health American Family Children's Hospital may be eligible. However, some children cannot join if they have certain medical conditions, are pregnant, or have taken specific medications recently. Those who join the trial will receive the sedative through the jet-injection system in their arm or thigh before their procedure. The study is not currently recruiting participants, but it will help improve how we care for children undergoing these procedures in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Referred to UW Health American Family Children's Hospital Pediatric Sedation Clinic for minimally invasive procedures such as blood draw, IV placement, or immunization
• • Age 2-15 years
• • Weight \<40kg
• Exclusion Criteria:
• • Participants with elevated intracranial pressure
• • Participants with uncontrolled hypertension
• • Participants who are pregnant or possibly pregnant (i.e., people of child bearing potential unable to provide a negative pregnancy test)
• • Participants who received a dose of medication within 2 hours of their appointment with the intention of sedation (i.e., benzodiazepines, opioids, alpha-2 agonists, 1st generation antihistamines)
• • Participants who are receiving medications which might enhance the sympathomimetic effect of ketamine (i.e., theophylline, aminophylline, amphetamine, or pseudoephedrine)
• • Participants who are receiving medications that might interfere with the expected pharmacokinetics of ketamine (i.e., ketoconazole, clarithromycin, rifampin, or carbamazepine)
• • Participant's parent/legal guardian requires a translator for communication about the patient's medical care